🇺🇸 FDA
Pipeline program

ALN-ANG3

ALN-ANG3-CKD-2502

Phase 2 small_molecule active

Quick answer

ALN-ANG3 for Diabetic Kidney Disease (DKD) is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Diabetic Kidney Disease (DKD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials